vs
LXP Industrial Trust（LXP）与MEDIFAST INC（MED）财务数据对比。点击上方公司名可切换其他公司
LXP Industrial Trust的季度营收约是MEDIFAST INC的1.2倍（$86.7M vs $75.1M），LXP Industrial Trust同比增速更快（-14.0% vs -36.9%），过去两年LXP Industrial Trust的营收复合增速更高（0.3% vs -34.4%）
LXP工业信托是一家公开上市的房地产投资信托，专注于持有、运营和投资美国核心市场的优质工业地产，主要涵盖配送中心、物流设施及轻型工业物业，服务电商、第三方物流、先进制造等领域租户，为投资者创造长期稳定收益。
迈德福斯特是一家总部位于美国马里兰州巴尔的摩的营养减重企业，该公司研发、分销并销售减重及健康相关产品，销售渠道涵盖官方网站、多层次营销、电话销售以及品牌加盟减重诊所。
LXP vs MED — 直观对比
营收规模更大
LXP
是对方的1.2倍
$75.1M
营收增速更快
LXP
高出22.9%
-36.9%
两年增速更快
LXP
近两年复合增速
-34.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $86.7M | $75.1M |
| 净利润 | $28.8M | — |
| 毛利率 | 81.5% | 69.4% |
| 营业利润率 | 34.6% | -10.4% |
| 净利率 | 33.2% | — |
| 营收同比 | -14.0% | -36.9% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $-1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LXPMED
| Q4 25 | $86.7M | $75.1M | ||
| Q3 25 | $86.9M | $89.4M | ||
| Q2 25 | $87.7M | $105.6M | ||
| Q1 25 | $88.9M | $115.7M | ||
| Q4 24 | $100.9M | $119.0M | ||
| Q3 24 | $85.6M | $140.2M | ||
| Q2 24 | $85.8M | $168.6M | ||
| Q1 24 | $86.3M | $174.7M |
净利润LXPMED
| Q4 25 | $28.8M | — | ||
| Q3 25 | $36.3M | $-2.3M | ||
| Q2 25 | $29.1M | $2.5M | ||
| Q1 25 | $19.0M | $-772.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $6.3M | $1.1M | ||
| Q2 24 | $5.4M | $-8.2M | ||
| Q1 24 | $-269.0K | $8.3M |
毛利率LXPMED
| Q4 25 | 81.5% | 69.4% | ||
| Q3 25 | 82.3% | 69.5% | ||
| Q2 25 | 81.9% | 72.6% | ||
| Q1 25 | 80.7% | 72.8% | ||
| Q4 24 | 85.3% | 74.1% | ||
| Q3 24 | 82.5% | 75.4% | ||
| Q2 24 | 82.0% | 73.2% | ||
| Q1 24 | 82.4% | 72.8% |
营业利润率LXPMED
| Q4 25 | 34.6% | -10.4% | ||
| Q3 25 | 50.4% | -4.6% | ||
| Q2 25 | 33.7% | -1.0% | ||
| Q1 25 | 21.8% | -1.1% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | 7.9% | 1.5% | ||
| Q2 24 | 6.9% | -4.7% | ||
| Q1 24 | 1.0% | 4.5% |
净利率LXPMED
| Q4 25 | 33.2% | — | ||
| Q3 25 | 41.7% | -2.5% | ||
| Q2 25 | 33.2% | 2.3% | ||
| Q1 25 | 21.4% | -0.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | 7.4% | 0.8% | ||
| Q2 24 | 6.3% | -4.8% | ||
| Q1 24 | -0.3% | 4.8% |
每股收益（稀释后）LXPMED
| Q4 25 | — | $-1.64 | ||
| Q3 25 | $0.12 | $-0.21 | ||
| Q2 25 | $0.09 | $0.22 | ||
| Q1 25 | $0.06 | $-0.07 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | $0.02 | $0.10 | ||
| Q2 24 | $0.01 | $-0.75 | ||
| Q1 24 | $-0.01 | $0.76 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $170.4M | $167.3M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $2.0B | $198.9M |
| 总资产 | $3.5B | $248.0M |
| 负债/权益比越低杠杆越低 | 0.66× | — |
8季度趋势，按日历期对齐
现金及短期投资LXPMED
| Q4 25 | $170.4M | $167.3M | ||
| Q3 25 | $229.7M | $173.5M | ||
| Q2 25 | $71.0M | $162.7M | ||
| Q1 25 | $70.9M | $164.6M | ||
| Q4 24 | $101.8M | $162.3M | ||
| Q3 24 | $55.0M | $170.0M | ||
| Q2 24 | $48.7M | $163.5M | ||
| Q1 24 | $293.8M | $156.4M |
总债务LXPMED
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LXPMED
| Q4 25 | $2.0B | $198.9M | ||
| Q3 25 | $2.1B | $214.7M | ||
| Q2 25 | $2.1B | $216.0M | ||
| Q1 25 | $2.1B | $211.0M | ||
| Q4 24 | $2.1B | $210.1M | ||
| Q3 24 | $2.1B | $207.3M | ||
| Q2 24 | $2.1B | $205.3M | ||
| Q1 24 | $2.2B | $211.0M |
总资产LXPMED
| Q4 25 | $3.5B | $248.0M | ||
| Q3 25 | $3.7B | $268.2M | ||
| Q2 25 | $3.7B | $269.3M | ||
| Q1 25 | $3.8B | $280.0M | ||
| Q4 24 | $3.8B | $284.2M | ||
| Q3 24 | $3.9B | $291.2M | ||
| Q2 24 | $3.9B | $293.5M | ||
| Q1 24 | $4.2B | $302.8M |
负债/权益比LXPMED
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $188.7M | $-5.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-6.6M |
| 自由现金流率自由现金流/营收 | — | -8.8% |
| 资本支出强度资本支出/营收 | — | 1.8% |
| 现金转化率经营现金流/净利润 | 6.56× | — |
| 过去12个月自由现金流最近4个季度 | — | $1.2M |
8季度趋势，按日历期对齐
经营现金流LXPMED
| Q4 25 | $188.7M | $-5.3M | ||
| Q3 25 | $63.5M | $12.1M | ||
| Q2 25 | $44.3M | $-3.4M | ||
| Q1 25 | $39.0M | $3.4M | ||
| Q4 24 | $211.2M | $-4.9M | ||
| Q3 24 | $64.6M | $9.1M | ||
| Q2 24 | $38.5M | $13.1M | ||
| Q1 24 | $38.9M | $7.3M |
自由现金流LXPMED
| Q4 25 | — | $-6.6M | ||
| Q3 25 | — | $10.8M | ||
| Q2 25 | — | $-4.8M | ||
| Q1 25 | — | $1.9M | ||
| Q4 24 | — | $-7.2M | ||
| Q3 24 | — | $7.7M | ||
| Q2 24 | — | $11.1M | ||
| Q1 24 | — | $5.4M |
自由现金流率LXPMED
| Q4 25 | — | -8.8% | ||
| Q3 25 | — | 12.0% | ||
| Q2 25 | — | -4.5% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | -6.1% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 3.1% |
资本支出强度LXPMED
| Q4 25 | — | 1.8% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.3% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.1% |
现金转化率LXPMED
| Q4 25 | 6.56× | — | ||
| Q3 25 | 1.75× | — | ||
| Q2 25 | 1.52× | -1.36× | ||
| Q1 25 | 2.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.18× | 8.04× | ||
| Q2 24 | 7.09× | — | ||
| Q1 24 | — | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
